878 related articles for article (PubMed ID: 31678528)
21. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.
Huang W; Chen K; Lu Y; Zhang D; Cheng Y; Li L; Huang W; He G; Liao H; Cai L; Tang Y; Zhao L; Pan M
Neoplasia; 2021 Dec; 23(12):1227-1239. PubMed ID: 34768109
[TBL] [Abstract][Full Text] [Related]
22. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption.
Lai Y; Lu N; Luo S; Wang H; Zhang P
J Med Chem; 2022 Oct; 65(19):13041-13051. PubMed ID: 36134739
[TBL] [Abstract][Full Text] [Related]
23. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
24. Spatially Asymmetric Nanoparticles for Boosting Ferroptosis in Tumor Therapy.
Hou M; Liu M; Yu H; Kou Y; Jia J; Zhou Q; Zhang F; Zhao D; Zhao T; Li X
Nano Lett; 2024 Jan; 24(4):1284-1293. PubMed ID: 38230643
[TBL] [Abstract][Full Text] [Related]
25. APE1 inhibition enhances ferroptotic cell death and contributes to hepatocellular carcinoma therapy.
Du Y; Zhou Y; Yan X; Pan F; He L; Guo Z; Hu Z
Cell Death Differ; 2024 Apr; 31(4):431-446. PubMed ID: 38418695
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.
Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X
Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744
[TBL] [Abstract][Full Text] [Related]
27. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
[TBL] [Abstract][Full Text] [Related]
28. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
29. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma.
Zhang L; Li XM; Shi XH; Ye K; Fu XL; Wang X; Guo SM; Ma JQ; Xu FF; Sun HM; Li QQ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2023 Mar; 44(3):622-634. PubMed ID: 36109580
[TBL] [Abstract][Full Text] [Related]
31. A ferroptosis amplifier based on triple-enhanced lipid peroxides accumulation strategy for effective pancreatic cancer therapy.
Chen M; Tong X; Sun Y; Dong C; Li C; Wang C; Zhang M; Wen Y; Ye P; Li R; Wan J; Liang S; Shi S
Biomaterials; 2024 Sep; 309():122574. PubMed ID: 38670032
[TBL] [Abstract][Full Text] [Related]
32. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2.
Varshosaz J; Raghami F; Rostami M; Jahanian A
J Liposome Res; 2019 Dec; 29(4):383-398. PubMed ID: 30668221
[TBL] [Abstract][Full Text] [Related]
33. Arginine-Rich Manganese Silicate Nanobubbles as a Ferroptosis-Inducing Agent for Tumor-Targeted Theranostics.
Wang S; Li F; Qiao R; Hu X; Liao H; Chen L; Wu J; Wu H; Zhao M; Liu J; Chen R; Ma X; Kim D; Sun J; Davis TP; Chen C; Tian J; Hyeon T; Ling D
ACS Nano; 2018 Dec; 12(12):12380-12392. PubMed ID: 30495919
[TBL] [Abstract][Full Text] [Related]
34. Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment.
Wang J; Zhang Y; Liu L; Cui Z; Liu X; Wang L; Li Y; Li Q
Drug Dev Ind Pharm; 2019 Sep; 45(9):1487-1495. PubMed ID: 31172835
[TBL] [Abstract][Full Text] [Related]
35. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs.
Su Y; Zhao B; Zhou L; Zhang Z; Shen Y; Lv H; AlQudsy LHH; Shang P
Cancer Lett; 2020 Jul; 483():127-136. PubMed ID: 32067993
[TBL] [Abstract][Full Text] [Related]
36. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
37. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.
Yu Y; Shen X; Xiao X; Li L; Huang Y
Small; 2023 Sep; 19(36):e2301149. PubMed ID: 37165608
[TBL] [Abstract][Full Text] [Related]
38. Targeted GSH-exhausting and hydroxyl radical self-producing manganese-silica nanomissiles for MRI guided ferroptotic cancer therapy.
Fei W; Chen D; Tang H; Li C; Zheng W; Chen F; Song Q; Zhao Y; Zou Y; Zheng C
Nanoscale; 2020 Aug; 12(32):16738-16754. PubMed ID: 32578659
[TBL] [Abstract][Full Text] [Related]
39. Ferroptosis in Liver Diseases: An Overview.
Capelletti MM; Manceau H; Puy H; Peoc'h K
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664576
[TBL] [Abstract][Full Text] [Related]
40. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib.
Wang X; Zhao L; Wang C; Wang L; Wu H; Song X; Wang W; Xu H; Dong X
Acta Biomater; 2023 Mar; 159():237-246. PubMed ID: 36736851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
